Revolution Medicines (NASDAQ:RVMD) Stock Price Expected to Rise, Wedbush Analyst Says

Revolution Medicines (NASDAQ:RVMD) had its target price lifted by equities researchers at Wedbush to $165.00 in a report released on Thursday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Wedbush’s price target would indicate a potential upside of 16.35% from the company’s current price.

A number of other brokerages have also commented on RVMD. Evercore reaffirmed an “outperform” rating on shares of Revolution Medicines in a report on Tuesday, April 14th. HC Wainwright reaffirmed a “buy” rating on shares of Revolution Medicines in a report on Wednesday, April 22nd. Jefferies Financial Group began coverage on Revolution Medicines in a report on Monday, March 16th. They issued a “buy” rating on the stock. Benchmark reaffirmed an “overweight” rating on shares of Revolution Medicines in a report on Tuesday, February 17th. Finally, Piper Sandler upped their price objective on Revolution Medicines to $172.00 and gave the company an “overweight” rating in a report on Thursday. Four research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Revolution Medicines presently has a consensus rating of “Buy” and a consensus price target of $103.88.

Revolution Medicines Stock Down 0.5%

RVMD stock opened at $141.81 on Thursday. The company has a current ratio of 7.14, a quick ratio of 7.14 and a debt-to-equity ratio of 0.16. The firm has a market capitalization of $30.15 billion, a PE ratio of -20.06 and a beta of 1.41. Revolution Medicines has a 1-year low of $34.00 and a 1-year high of $155.70. The business’s 50 day simple moving average is $113.41 and its 200 day simple moving average is $94.43.

Revolution Medicines (NASDAQ:RVMD) last posted its earnings results on Wednesday, May 6th. The company reported ($2.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.83) by ($0.46). During the same period last year, the business earned ($1.13) earnings per share. As a group, research analysts anticipate that Revolution Medicines will post -7.42 EPS for the current year.

Insider Activity

In other news, COO Margaret A. Horn sold 4,583 shares of the company’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total transaction of $455,916.84. Following the completion of the sale, the chief operating officer directly owned 157,570 shares in the company, valued at approximately $15,675,063.60. This represents a 2.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Stephen Michael Kelsey sold 4,302 shares of the company’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total value of $427,962.96. Following the sale, the insider owned 295,398 shares of the company’s stock, valued at approximately $29,386,193.04. The trade was a 1.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 184,592 shares of company stock worth $24,499,532. 8.20% of the stock is owned by insiders.

Institutional Trading of Revolution Medicines

A number of institutional investors have recently modified their holdings of RVMD. Indiana Trust & Investment Management Co bought a new stake in shares of Revolution Medicines during the 4th quarter valued at $32,000. Global Retirement Partners LLC lifted its position in shares of Revolution Medicines by 1,002.8% during the 4th quarter. Global Retirement Partners LLC now owns 397 shares of the company’s stock valued at $32,000 after acquiring an additional 361 shares during the period. Torren Management LLC bought a new stake in shares of Revolution Medicines during the 4th quarter valued at $33,000. Arax Advisory Partners bought a new stake in shares of Revolution Medicines during the 4th quarter valued at $38,000. Finally, Darwin Wealth Management LLC bought a new stake in shares of Revolution Medicines during the 4th quarter valued at $40,000. 94.34% of the stock is currently owned by institutional investors.

Trending Headlines about Revolution Medicines

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Piper Sandler raised its price target on Revolution Medicines to $172 and reiterated an overweight view, adding to recent bullish calls from other firms and reinforcing confidence in the company’s growth outlook. Revolution Medicines (NASDAQ:RVMD) Price Target Raised to $172.00 at Piper Sandler
• Positive Sentiment: Revolution Medicines announced publication of Phase 1/2 daraxonrasib data in the New England Journal of Medicine, strengthening the scientific case for its pivotal RASolute 302 pancreatic cancer trial. Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer
• Positive Sentiment: Reuters reported that the company’s experimental pancreatic cancer drug showed a strong survival benefit in trials, which could boost confidence in RVMD’s lead program and long-term pipeline value. Promising Revolution Medicines pancreatic cancer drug has high rate of mostly manageable side effects
• Neutral Sentiment: Q1 earnings showed a wider-than-expected loss and the company raised its 2026 expense outlook, underscoring that RVMD is still investing heavily in R&D and commercial preparation. RVMD Reports Wider-Than-Expected Loss in Q1, Raises ’26 Expense View
• Neutral Sentiment: TipRanks highlighted a new warrant-related risk ahead of the 2026 expiry, noting possible dilution concerns and the possibility that the warrants could expire worthless, which adds a layer of uncertainty for shareholders. Revolution Medicines Warrants: Balancing Dilution Risk and Potential Worthlessness Ahead of 2026 Expiry
• Negative Sentiment: Despite the clinical progress, higher losses and rising spending could weigh on sentiment if investors focus on the company’s need for continued funding before any product revenue arrives. Revolution Medicines, Inc. (RVMD) Q1 2026 Earnings Call Transcript

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.